Flexibility meets precision in next-generation extracellular vesicle analysis
The Challenge: Capturing the Complexity of Neurological Disease
Neurological diseases don’t operate in isolation. Alzheimer’s, Parkinson’s, ALS, and other neurodegenerative conditions involve intricate interactions between neurons, astrocytes, microglia, immune cells, and peripheral systems. Yet traditional biomarker platforms often force researchers to make impossible choices—measure neuronal markers or glial markers, track disease proteins or vesicle characteristics, focus on the brain or systemic signals.
At NeuroDex, we believe the future of neuroscience diagnostics requires a different approach: one that embraces complexity rather than simplifying it away.
Introducing Our Validated Biomarker Panel
Today, we’re proud to share a milestone in our journey: a growing library of over 30 biomarkers successfully validated on the LuminEV™ platform. This isn’t just a list—it’s a testament to our commitment to giving researchers the tools they need to ask better questions and find better answers.
Extracellular Vesicle Markers
TSPN, CD9, CD63, CD81
These foundational markers confirm the extracellular vesicle origin of your samples, ensuring data quality and reproducibility across studies.
Neuronal Markers
GRIN2A, GAP43, GRIK2, CNTN5, NRXN1, NRGN, NLGN1, NLGN3
From synaptic proteins to neuronal growth factors, these markers provide direct insight into neuronal health, plasticity, and signaling in both development and disease.
Brain-Specific Markers
PLP1, ODN, AQP4
Oligodendrocyte and astrocyte markers that help distinguish brain-derived signals from peripheral noise, critical for CNS-specific analysis.
Glial Cell Markers
P2RY12 (Microglia)
Microglial activation plays a central role in neuroinflammation and disease progression. Tracking these markers opens windows into immune dynamics within the brain.
Disease-Relevant Proteins
TDP-43, pTDP-43, α-synuclein
The molecular hallmarks of ALS, frontotemporal dementia, and Parkinson’s disease. Measuring these proteins in extracellular vesicles offers a minimally invasive window into disease pathology.
Immune and Non-Neuronal Markers
CD41, CD42 (Platelets) | CD68 (Macrophages) | CD47 (Macrophage Avoidance)
Because neurological diseases often involve systemic inflammation, vascular dysfunction, and immune dysregulation, tracking these peripheral signals provides critical context.
Systemic Markers
Podocin (Kidney) | CD235a (Erythrocytes)
Even markers from kidney and red blood cells can inform our understanding of multi-system involvement in neurodegenerative disease.
Why Multiplexing Matters
The power of LuminEV™ isn’t just in the number of markers—it’s in the ability to measure them simultaneously from the same sample. This multiplexed approach offers several key advantages:
- Comprehensive Disease ProfilingRather than looking at neurons in isolation, researchers can now capture the interplay between neuronal dysfunction, glial activation, immune responses, and systemic changes—all in one assay.
- Sample EfficiencyPrecious clinical samples go further when you can extract maximum information from minimal volume.
- Mechanistic InsightsUnderstanding how different cell types and pathways interact is essential for identifying therapeutic targets and predicting treatment response.
- Clinical Trial ReadinessFrom patient stratification to pharmacodynamic endpoints, multiplexed biomarker panels provide the precision needed for modern drug development.
From Discovery to Clinic
LuminEV™ is designed to support the full research continuum:
Early Discovery: Explore novel biomarker combinations and disease mechanisms without being constrained by platform limitations.
Biomarker Validation: Rigorously test candidate markers across diverse patient populations with robust, reproducible assays.
Clinical Trials: Deploy validated panels as trial endpoints, enabling faster decisions and more informative data.
Precision Medicine: Develop patient stratification strategies based on multi-dimensional biomarker profiles.
The Road Ahead
This biomarker library represents where we are today—but it’s far from where we’re going. As neuroscience evolves and new disease mechanisms emerge, LuminEV™ will continue to expand, adapt, and push the boundaries of what’s possible in liquid biopsy diagnostics.
We’re building more than a platform. We’re building an ecosystem for discovery.
Partner With Us
Whether you’re an academic researcher exploring fundamental questions or a biopharma team developing the next breakthrough therapy, NeuroDex is here to help you unlock the potential of extracellular vesicle biomarkers.
